Variability of insulin degludec and glargine 300 U/mL: A matter of methodology or just marketing?
Diabetes Obes Metab
.
2018 Sep;20(9):2051-2056.
doi: 10.1111/dom.13365.
Epub 2018 Jun 10.
Authors
Tim Heise
1
,
Sascha Heckermann
1
,
J Hans DeVries
1
Affiliation
1
Profil, Neuss, Germany.
PMID:
29770552
DOI:
10.1111/dom.13365
No abstract available
Publication types
Comment
MeSH terms
Diabetes Mellitus, Type 1*
Humans
Hypoglycemic Agents
Insulin Glargine
Insulin, Long-Acting
Marketing
Substances
Hypoglycemic Agents
Insulin, Long-Acting
Insulin Glargine
insulin degludec